Skip to Content
Merck
All Photos(1)

Documents

Safety Information

SCP0153

Sigma-Aldrich

GLP-1 (Preproglucagon 72-107 amide) (GLP-1 human)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C184H273N51O57
Molecular Weight:
4111.44
UNSPSC Code:
12352200
NACRES:
NA.32

Assay

≥95% (HPLC)

form

lyophilized

composition

Peptide Content, ≥75%

storage condition

protect from light

storage temp.

−20°C

Amino Acid Sequence

His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2

Application

GLP-1 (Preproglucagon 72-107 amide) (GLP-1 human) has been used to study its effect on vascular endothelial growth factor-A (VEGFA)-mediated endothelium-dependent signaling and vasodilation.
Glycogen-like peptide-1 (GLP-1) is an amino acid peptide derived from proglucogon. GLP-1 is involved in the regulation of the glycemic index via its affect on glucagon and insulin levels. GLP-1 may be used to study its interaction with its receptor, the GLP-1 receptor.

Biochem/physiol Actions

Glycogen-like peptide-1 (GLP-1) is an insulinotropic hormone, which takes part in increasing insulin secretion and insulin sensitivity. It also inhibits the secretion of glycogen and reduces fasting glucose levels.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SCP0153-500UG:
SCP0153-1MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries
Egholm C, et al.
American Journal of Physiology. Heart and Circulatory Physiology, 311(5), H1214-H1224 (2016)
Voglibose: an alpha-glucosidase inhibitor
Dabhi AS, et al.
Journal of Clinical and Diagnostic Research : JCDR, 7(12), 3023-3023 (2013)
Alaa Al Helaili et al.
Biochemical and biophysical research communications, 533(1), 110-117 (2020-09-19)
Dysfunction of the gut-brain axis is one of the potential contributors to the pathophysiology of obesity and is therefore a potential target for treatment. Vagal afferents innervating the gut play an important role in controlling energy homeostasis. There is an
Fan Xiao et al.
Frontiers in cardiovascular medicine, 8, 709741-709741 (2021-09-14)
Objectives: This study explores the concentration and role of glucagon-like peptide-1 (GLP-1) in calcific aortic valve disease (CAVD). Background: Calcific aortic valve disease is a chronic disease presenting with aortic valve degeneration and mineralization. We hypothesized that the level of
Cecilie Egholm et al.
American journal of physiology. Heart and circulatory physiology, 311(5), H1214-H1224 (2016-11-03)
We investigated the acute effects of glucagon-like peptide-1 (GLP-1), GLP-1(1-36), and GLP-1(7-36) on vascular endothelial growth factor-A (VEGFA)-induced endothelium-dependent signaling and vasodilation. Our hypothesis was that GLP-1 released from intestinal l-cells modulates processes related to PLCγ activation, Src, and endothelial

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service